Navigation Links
Oramed Announces Last Patient Out in Phase 2a FDA Trial of its ORMD-0801 Oral Insulin Capsule
Date:11/12/2013

s. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Office: +972-2-566-0001   
Int'l: 1-718-831-2512    
Mobile: +972-54-792-4438
Email: aviva@oramed.com 


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orameds Platform Technology in Oral Delivery of Proteins Receives Patent in Russia
2. Oramed Granted Patent in China for its Platform Technology in Oral Delivery of Proteins
3. Oramed Submits Pre-IND Meeting Request to FDA for its Oral Exenatide Capsule ORMD-0901
4. Oramed to Raise $4,600,000 in Registered Direct Offering
5. Oramed Pharmaceuticals to Present Findings on Oral Insulin to the American Diabetes Association
6. Oramed Pharmaceuticals Announces Withdrawal of Proposed Underwritten Public Offering
7. Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel
8. Oramed Selected to Present at the 81st European Atherosclerosis Society Congress in Lyon, France, June 2-5, 2013
9. Oramed Pharmaceuticals Awarded Grant by the Office of the Chief Scientist of Israel
10. Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
11. Clinical Results for Orameds Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  WebMD ... leading source of health information, today announced ... new National Action Plan for Combating ... Obama emphasized the urgency and importance of ... national and global health.    The ...
(Date:3/26/2015)... /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the ... Omega-3 therapies for cardiovascular disease and overall health, announced ... shares of the Corporation (the "Common Shares"). The Common ... December 5 th , 2014 to March 4 th ... due on or before April 1, 2015. Interest on ...
(Date:3/26/2015)... , March 26, 2015 "Whether it,s our ... one day." In a single sentence, ... scientific officer at Pfizer,s Centers for Therapeutic Innovation ... scientists fueling progress at America,s biopharmaceutical companies. ... side-by-side with academia, patient foundations and the National Institutes ...
Breaking Medicine Technology:Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2
... Pain relieving effects of MoxDuo(TM) IR are ... with post-operative pain following total knee replacement , ... QRxPharma Limited (ASX: QRX) and (OTCQX: QRXPY) announced today ... efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules ...
... , THOUSAND OAKS, Calif., Aug. 25 Amgen (Nasdaq: ... double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease ... rial to R educe Cardiovascular E ndpoints with ... Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had ...
Cached Medicine Technology:MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R) 2MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R) 3MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R) 4Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 2Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 3Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 4Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 5Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 6Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 7Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes 8
(Date:3/30/2015)... A new recruitment site has been launched ... next career move. , Millions of new jobs are ... with skills in the booming data and analytics sectors.* ... jobs aggregator, pulling in opportunities from both employers and ... to help candidates find suitable big data and analytics ...
(Date:3/30/2015)... 30, 2015 BioFit ... and manufacturer of ergonomic seating solutions, now ... The new upholsteries bolster the company’s existing ... seating, providing disinfectable, green choices. , The ... textile purveyor CF Stinson. Six disinfectable patterns ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 Bunion Bootie ... discomfort. Buy them for family members, friends...and yourself and save. ... customers can save an additional 10%, on top of discounts ... promo code "EasterPR" at checkout. The more Bunion Booties purchased, ... toe spacers, and bunion pads, Bunion Bootie can be worn ...
(Date:3/29/2015)... Calif. (PRWEB) March 30, 2015 Over ... menopause-related symptoms tied to undiagnosed autoimmune, thyroid, or hormone ... thyroid disorders, has personally treated hundreds of patients dealing ... are unaware of the treatment options for their ailments. ... offers solutions to women living with fatigue, brain fog, ...
(Date:3/29/2015)... Birmingham, Lake Orion, Clarkston, Metamora, MI. (PRWEB) March 29, ... affiliated with Beaumont Hospital , offers comprehensive endometriosis ... now offer patients in that area a closer hospital ... St. Joseph Mercy Oakland and McLaren Oakland. ... tissue that normally lines the inside of the uterus ...
Breaking Medicine News(10 mins):Health News:New Global Job Site Launched for Big Data and Analytics Job Seekers 2Health News:BioFit Adds Bleachable Upholstery Options to Seating Line 2Health News:Bunion Bootie, the Ultimate Solution for Bunion Relief, Offers Special Savings This Easter 2Health News:How to Turn Mid-life into the Good Life 2Health News:Women's Excellence Affiliates with Beaumont Hospital, Treats Endometriosis 2
... Institute of Technology Kanpur have discovered that the mechanism that ... stream can, in certain circumstances, collapse into a state which ... This process could provide the first insight into how iron ... Parkinsons & Alzheimers and Huntingtons diseases. , Human blood relies ...
... Products,Inc. (Nasdaq: AHPI ) reported today that its net ... percent from $293,000 last year,or 4 cents per share, to ... For the first half of the 2008 fiscal year ... $495,000 last year, or six cents,per share, to about $93,500, ...
... 8 Today, Congresswoman,Stephanie Tubbs Jones announced that ... for the Louis Stokes Cleveland VA Medical,Center by ... the new,construction was made possible by a $397 ... construction under the final 2008,Appropriations bill signed into ...
... tool powered by SNAPforSeniors(R) helps members quickly,locate safe housing, ... rash of tornadoes in more than 20 years destroyed ... Tennessee Tuesday night., Emergency warnings gave most residents ... housing, natural disasters bring extra fears. Lack,of mobility, limited ...
... Inc. (Nasdaq:,HWKN) today announced third quarter and nine months ... 2007, Hawkins reported sales,increased 30.9% to $48.5 million versus ... income for the quarter was $1.5 million, equal to ... $0.03 per diluted share,for the third quarter of fiscal ...
... sleep disturbances , , FRIDAY, Feb. 8 (HealthDay News) -- ... as bad as what people experience when they stop ... new study says. , "These results indicate that ... to quit, and that these effects should be considered ...
Cached Medicine News:Health News:Iron banded worms drying out of blood could be linked to Parkinson's and Alzheimer's 2Health News:Allied Healthcare's Net Suffers on Flat Sales, Performance Issues 2Health News:Allied Healthcare's Net Suffers on Flat Sales, Performance Issues 3Health News:Allied Healthcare's Net Suffers on Flat Sales, Performance Issues 4Health News:Allied Healthcare's Net Suffers on Flat Sales, Performance Issues 5Health News:Tennessee Tornadoes Spur Senior Move Managers to Aid Elderly in Crisis 2Health News:Tennessee Tornadoes Spur Senior Move Managers to Aid Elderly in Crisis 3Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 2Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 3Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 4Health News:Quitting Marijuana Just as Hard as Quitting Cigarettes 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: